City

Clinical trials near Miami, United States

Active studies with a listed research site in Miami, United States.

40active studies

23recruiting now

12countries represented

74largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Obesity, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Japan, Puerto Rico37 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684144See eligibility →

Recruiting nowPhase 3

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Obesity, OverweightCondition

aleniglipron, aleniglipronTreatment

United States74 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-09-01 · NCT07654374See eligibility →

Recruiting nowPhase 3

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Obesity or OverweightCondition

Maridebart CafraglutideTreatment

Puerto Rico, United States45 locations

AmgenSponsor

Updated 2026-08-27 · NCT07575399See eligibility →

Recruiting nowPhase 2

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

Overweight, ObesityCondition

PF-08653945, PF-08653944Treatment

Canada, United States65 locations

PfizerSponsor

Updated 2026-08-17 · NCT07575932See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Obesity, OverweightCondition

Aleniglipron, PlaceboTreatment

United States71 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-08-10 · NCT07654361See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowPhase 1

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

Overweight or Obese Adults, Overweight or Obese, Type 2 DiabetesCondition

ALV-100, PlaceboTreatment

United States2 locations

Alveus Therapeutics, Inc.Sponsor

Updated 2026-07-23 · NCT07399678See eligibility →

Recruiting nowPhase 1

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Cardiometabolic DiseaseCondition

AMG 513, PlaceboTreatment

United States10 locations

AmgenSponsor

Updated 2026-06-22 · NCT06585462See eligibility →

Recruiting nowPhase 1

Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)

Weight ManagementCondition

GS-4571, PlaceboTreatment

United States3 locations

Gilead SciencesSponsor

Updated 2026-06-22 · NCT06562907See eligibility →

Recruiting nowPhase 2

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

Obesity and Cardiovascular RiskCondition

Oral BGE-102, Oral Placebo Matching BGE-102Treatment

Puerto Rico, United States13 locations

BioAge Labs, Inc.Sponsor

Updated 2026-06-18 · NCT07656727See eligibility →

Recruiting nowNot applicable

Spinal Cord Injury Model Systems (SCIMS) - Education Module

Spinal Cord Injuries, ObesityCondition

PVA Consumer Guide, WebMDTreatment

United States3 locations

University of MiamiSponsor

Updated 2026-04-20 · NCT06003686See eligibility →

Recruiting nowPhase 4

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Type2Diabetes, ASCVDCondition

SGLT2 inhibitor, GLP-1 receptor agonistTreatment

United States36 locations

Brigham and Women's HospitalSponsor

Updated 2026-04-13 · NCT05390892See eligibility →

Recruiting nowPhase 1

First in Human Study in Subjects With Obesity, But Otherwise Healthy

ObesityCondition

DA-1726, Placebo to DA-1726Treatment

United States1 locations

NeuroBo Pharmaceuticals Inc.Sponsor

Updated 2026-04-09 · NCT06252220See eligibility →

Recruiting nowPhase 4

Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

Crohn DiseaseCondition

Tirzepatide, Mediterranean dietTreatment

United States1 locations

University of MiamiSponsor

Updated 2026-03-30 · NCT06774079See eligibility →

Recruiting nowNot applicable

Efficacy Trial of Healthy Together ("Juntos")

Obesity, Activity, MotorCondition

Healthy Together ("Juntos")Treatment

United States1 locations

University of MiamiSponsor

Updated 2026-03-23 · NCT06489262See eligibility →

Recruiting nowPhase 2

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

Type II Diabetes MellitusCondition

GL0034 Dose Level 1, GL0034 Dose Level 2Treatment

India, United States21 locations

Sun Pharmaceutical Industries LimitedSponsor

Updated 2026-03-18 · NCT07282743See eligibility →

Recruiting nowNot applicable

Bikini vs Longitudinal Incision in Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)

THACondition

Bikini Incision, Longitudinal IncisionTreatment

United States1 locations

University of MiamiSponsor

Updated 2026-03-18 · NCT06831045See eligibility →

Recruiting nowNot applicable

With Love, Grandma ("Con Cariño, Abuelita") Pilot Study

Cancer, Breast, Cancer, UterusCondition

With Love, Grandma ("Con Cariño, Abuelita")Treatment

United States1 locations

University of Miami Sylvester Comprehensive Cancer CenterSponsor

Updated 2026-02-25 · NCT05721976See eligibility →

Recruiting nowNot applicable

Community Park-Based Programs for Health Promotion: The Fit2Lead Prospective Cohort Study

Anxiety, Wellness, PsychologicalCondition

Fit2Lead Group 1-2Treatment

United States1 locations

Duke UniversitySponsor

Updated 2025-09-10 · NCT06596265See eligibility →

Recruiting nowNot applicable

Community Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study

Overweight, ObesityCondition

Fit2Play curriculumTreatment

United States1 locations

Duke UniversitySponsor

Updated 2025-09-04 · NCT06595251See eligibility →

Recruiting nowNot applicable

Community Park-Based Programs for Health Promotion: Active Older Adults Prospective Cohort Study

Hypertension, OverweightCondition

Active older AdultsTreatment

United States1 locations

Duke UniversitySponsor

Updated 2025-09-04 · NCT06604650See eligibility →

Recruiting nowNot applicable

RESET System Pivotal Trial (Rev F)

Diabetes type2, ObesityCondition

RESET Liner, ShamTreatment

United States7 locations

Morphic Medical Inc.Sponsor

Updated 2024-07-18 · NCT04101669See eligibility →

Opening soonPhase 1

A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

Diabetes Mellitus, Type 1, OverweightCondition

Tirzepatide, AcetaminophenTreatment

United States1 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT07803744See eligibility →

Opening soonNot applicable

PLAY2CONTROL Study

Type 2 Diabetes, Obesity & OverweightCondition

Nex Playground Activity ProgramTreatment

United States1 locations

University of MiamiSponsor

Updated 2026-08-27 · NCT07556679See eligibility →

Opening soonPhase 3

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Overweight, ObesityCondition

Zenagamtide, SemaglutideTreatment

United States43 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07668414See eligibility →

Active, not recruitingPhase 2

Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

Obesity & Overweight, Mobility DisabilityCondition

Enobosarm, Semaglutide (Wegovy) weekly injectionTreatment

United States13 locations

Veru Inc.Sponsor

Updated 2026-09-04 · NCT07446998See eligibility →

Active, not recruitingPhase 1, Phase 2

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)Condition

ALN-4324, PlaceboTreatment

Argentina, Canada22 locations

Alnylam PharmaceuticalsSponsor

Updated 2026-08-14 · NCT06845202See eligibility →

Active, not recruitingNot applicable

NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors

Obesity, Childhood, CancerCondition

NOURISH-T+, Brief NOURISH-T+Treatment

United States10 locations

University of South FloridaSponsor

Updated 2026-08-12 · NCT04656496See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

Argentina, Canada40 locations

Eli Lilly and CompanySponsor

Updated 2026-07-23 · NCT07035093See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingPhase 1

A Study of LY3971297 in Healthy Participants

Healthy, ObesityCondition

LY3971297, PlaceboTreatment

Japan, Singapore7 locations

Eli Lilly and CompanySponsor

Updated 2026-07-16 · NCT06148272See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Obesity, OverweightCondition

RetatrutideTreatment

Argentina, Canada35 locations

Eli Lilly and CompanySponsor

Updated 2026-06-09 · NCT07357415See eligibility →

Active, not recruitingPhase 1

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

Obese But Otherwise Healthy ParticipantsCondition

CRB-913, PlaceboTreatment

United States15 locations

Corbus Pharmaceuticals Inc.Sponsor

Updated 2026-05-29 · NCT07310901See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Obesity, OverweightCondition

Bimagrumab, TirzepatideTreatment

United States12 locations

Eli Lilly and CompanySponsor

Updated 2026-05-26 · NCT06643728See eligibility →

Active, not recruitingPhase 2

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

ObesityCondition

NT-0796, PlaceboTreatment

United States9 locations

NodThera LimitedSponsor

Updated 2026-04-08 · NCT07220629See eligibility →

Active, not recruitingPhase 2

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Type 2 Diabetes, ObesityCondition

Tirzepatide, PlaceboTreatment

Argentina, Mexico40 locations

Eli Lilly and CompanySponsor

Updated 2026-03-23 · NCT06037252See eligibility →

Active, not recruitingNot applicable

Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide

Obesity, Weight Change TrajectoryCondition

Revita Duodenal Mucosal Resurfacing (DMR), ShamTreatment

United States32 locations

Fractyl Health Inc.Sponsor

Updated 2026-03-03 · NCT06484114See eligibility →

Active, not recruitingPhase 2

Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Endocrinology, Diabetes, Type IICondition

AZD6234, Placebo to matchTreatment

United States18 locations

AstraZenecaSponsor

Updated 2026-03-03 · NCT06851858See eligibility →

Active, not recruitingPhase 1

A Study of LY3537031 in Overweight, Obese, and Healthy Participants

Overweight, ObesityCondition

LY3537031, PlaceboTreatment

United States5 locations

Eli Lilly and CompanySponsor

Updated 2026-01-20 · NCT06606106See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Miami, United States

Current studies

Related cities